{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=etanercept%28Enbrel%C2%AE%29",
    "query": {
      "intervention": "etanercept(Enbrel®)"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 23,
    "total_pages": 3,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=etanercept%28Enbrel%C2%AE%29&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-10-05T03:51:23.298Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01716637",
      "title": "Short Term Efficacy and Safety of Perispinal Administration of Etanercept in Mild to Moderate Alzheimer's Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Alzheimer's Disease"
      ],
      "interventions": [
        {
          "name": "Etanercept",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Curcum.Luteol.Theaflav.Lip.Acid,FishOil,Quercet.,Resveratr.",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "Life Extension Foundation Inc.",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "60 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "60 Years to 85 Years"
      },
      "enrollment_count": 12,
      "start_date": "2010-02",
      "completion_date": "2016-05",
      "has_results": false,
      "last_update_posted_date": "2016-05-12",
      "last_synced_at": "2026-10-05T03:51:23.298Z",
      "location_count": 2,
      "location_summary": "Coral Springs, Florida • Delray Beach, Florida",
      "locations": [
        {
          "city": "Coral Springs",
          "state": "Florida"
        },
        {
          "city": "Delray Beach",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01716637"
    },
    {
      "nct_id": "NCT00679042",
      "title": "Islet Transplantation in Type 1 Diabetic Patients Using the University of Illinois at Chicago (UIC) Protocol",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Type 1 Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "Islets of Langerhans transplantation",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "CellTrans Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 21,
      "start_date": "2007-09-05",
      "completion_date": "2026-06-14",
      "has_results": true,
      "last_update_posted_date": "2026-04-06",
      "last_synced_at": "2026-10-05T03:51:23.298Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00679042"
    },
    {
      "nct_id": "NCT00421174",
      "title": "Effectiveness of Etanercept for Idiopathic Pneumonia Syndrome Following Stem Cell Transplantation (BMT CTN 0403)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pneumonia",
        "Idiopathic Pneumonia Syndrome"
      ],
      "interventions": [
        {
          "name": "Etanercept",
          "type": "DRUG"
        },
        {
          "name": "Placebo plus corticosteroid",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Heart, Lung, and Blood Institute (NHLBI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 37,
      "start_date": "2007-08",
      "completion_date": "2013-07",
      "has_results": true,
      "last_update_posted_date": "2021-11-01",
      "last_synced_at": "2026-10-05T03:51:23.298Z",
      "location_count": 12,
      "location_summary": "Gainesville, Florida • Indianapolis, Indiana • Baltimore, Maryland + 9 more",
      "locations": [
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00421174"
    },
    {
      "nct_id": "NCT00201682",
      "title": "Etanercept and Rituximab in Patients With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Chronic Lymphocytic Leukemia",
        "Small Lymphocytic Lymphoma"
      ],
      "interventions": [
        {
          "name": "Etanercept",
          "type": "DRUG"
        },
        {
          "name": "Rituximab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "John Byrd",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 36,
      "start_date": "2002-10",
      "completion_date": "2009-08",
      "has_results": false,
      "last_update_posted_date": "2017-02-08",
      "last_synced_at": "2026-10-05T03:51:23.298Z",
      "location_count": 1,
      "location_summary": "Columbus, Ohio",
      "locations": [
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00201682"
    },
    {
      "nct_id": "NCT02638259",
      "title": "Comparative Efficacy and Safety Study of GP2015 and Enbrel® in Patients With Rheumatoid Arthritis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Rheumatoid Arthritis"
      ],
      "interventions": [
        {
          "name": "GP2015",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sandoz",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 376,
      "start_date": "2015-02-21",
      "completion_date": "2017-06-12",
      "has_results": true,
      "last_update_posted_date": "2018-09-19",
      "last_synced_at": "2026-10-05T03:51:23.298Z",
      "location_count": 26,
      "location_summary": "Peoria, Arizona • Phoenix, Arizona • El Cajon, California + 21 more",
      "locations": [
        {
          "city": "Peoria",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "El Cajon",
          "state": "California"
        },
        {
          "city": "Upland",
          "state": "California"
        },
        {
          "city": "Van Nuys",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02638259"
    },
    {
      "nct_id": "NCT02451748",
      "title": "IL-7 and IL-7R Expression in RA Patients With Active vs. Inactive Disease Treated With DMARD or CIMZIA",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Rheumatoid Arthritis"
      ],
      "interventions": [
        {
          "name": "Lab Work",
          "type": "OTHER"
        },
        {
          "name": "Certolizumab pegol (CDP870, tradename Cimzia)(prefilled syringes at the dose of 200mg)",
          "type": "DRUG"
        },
        {
          "name": "Certolizumab pegol (CDP870, tradename Cimzia)",
          "type": "DRUG"
        },
        {
          "name": "Hydroxychloroquine",
          "type": "DRUG"
        },
        {
          "name": "Sulfasalazine",
          "type": "DRUG"
        },
        {
          "name": "Medrol",
          "type": "DRUG"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        },
        {
          "name": "Triamcinolone",
          "type": "DRUG"
        },
        {
          "name": "Naproxen",
          "type": "DRUG"
        },
        {
          "name": "Leflunomide",
          "type": "DRUG"
        },
        {
          "name": "Methotrexate",
          "type": "DRUG"
        },
        {
          "name": "humira",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG"
      ],
      "sponsor": "University of Illinois at Chicago",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 32,
      "start_date": "2015-08",
      "completion_date": "2017-12",
      "has_results": true,
      "last_update_posted_date": "2024-07-10",
      "last_synced_at": "2026-10-05T03:51:23.298Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02451748"
    },
    {
      "nct_id": "NCT02112097",
      "title": "ASIS for Enbrel in Plaque Psoriasis",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Plaque Psoriasis."
      ],
      "interventions": [
        {
          "name": "Gadolinium",
          "type": "DRUG"
        },
        {
          "name": "Efficacy of Enbrel subcutaneously at Week 12",
          "type": "DRUG"
        },
        {
          "name": "Efficacy of Enbrel subcutaneously at Week 24",
          "type": "DRUG"
        },
        {
          "name": "Efficacy of Enbrel subcutaneously at Week 36",
          "type": "DRUG"
        },
        {
          "name": "Efficacy of Enbrel subdermally at Week 12",
          "type": "DRUG"
        },
        {
          "name": "Efficacy of Enbrel subdermally at Week 24",
          "type": "DRUG"
        },
        {
          "name": "Efficacy of Enbrel subdermally at Week 36",
          "type": "DRUG"
        },
        {
          "name": "PASI 75 n(%) subcutaneously at Week 12",
          "type": "DRUG"
        },
        {
          "name": "PASI 75 n(%) subcutaneously at Week 24",
          "type": "DRUG"
        },
        {
          "name": "PASI 75 n(%) subcutaneously at Week 36",
          "type": "DRUG"
        },
        {
          "name": "PASI 75 n(%) subdermally at Week 12",
          "type": "DRUG"
        },
        {
          "name": "PASI 75 n(%) subdermally at Week 24",
          "type": "DRUG"
        },
        {
          "name": "PASI 75 n(%) subdermally at Week 36",
          "type": "DRUG"
        },
        {
          "name": "Adverse Reactions of Enbrel subcutaneously",
          "type": "DRUG"
        },
        {
          "name": "Adverse Reactions of Enbrel subdermally at Week 36",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ASIS Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "21 Years to 65 Years"
      },
      "enrollment_count": 60,
      "start_date": "2016-01",
      "completion_date": "2017-06",
      "has_results": false,
      "last_update_posted_date": "2015-06-24",
      "last_synced_at": "2026-10-05T03:51:23.298Z",
      "location_count": 1,
      "location_summary": "Westminster, California",
      "locations": [
        {
          "city": "Westminster",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02112097"
    },
    {
      "nct_id": "NCT01901185",
      "title": "Study to Evaluate the Ability of Subjects With Rheumatoid Arthritis or Psoriatic Arthritis to Effectively Use a Reusable Autoinjector to Self-inject Etanercept",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Rheumatoid Arthritis",
        "Psoriatic Arthritis"
      ],
      "interventions": [
        {
          "name": "Etanercept / Autoinjector A",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 77,
      "start_date": "2013-06-11",
      "completion_date": "2013-12-30",
      "has_results": true,
      "last_update_posted_date": "2018-09-04",
      "last_synced_at": "2026-10-05T03:51:23.298Z",
      "location_count": 13,
      "location_summary": "Huntsville, Alabama • Peoria, Arizona • Phoenix, Arizona + 10 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Peoria",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Santa Maria",
          "state": "California"
        },
        {
          "city": "Upland",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01901185"
    },
    {
      "nct_id": "NCT00141713",
      "title": "The Use of Etanercept (Enbrel®) in the Treatment of Acute Graft-Versus-Host Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Graft-Versus-Host Disease"
      ],
      "interventions": [
        {
          "name": "Etanercept",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Michigan Rogel Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 40,
      "start_date": "2003-10",
      "completion_date": "2006-12",
      "has_results": false,
      "last_update_posted_date": "2013-03-13",
      "last_synced_at": "2026-10-05T03:51:23.298Z",
      "location_count": 1,
      "location_summary": "Ann Arbor, Michigan",
      "locations": [
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00141713"
    },
    {
      "nct_id": "NCT04559412",
      "title": "Study to Assess the Safety and Efficacy of Enbrel Administered by Sofusa DoseConnect for Rheumatoid Arthritis",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Rheumatoid Arthritis"
      ],
      "interventions": [
        {
          "name": "Sofusa DoseConnect",
          "type": "DEVICE"
        },
        {
          "name": "Enbrel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "DRUG"
      ],
      "sponsor": "Sorrento Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 11,
      "start_date": "2021-03-15",
      "completion_date": "2024-12",
      "has_results": false,
      "last_update_posted_date": "2023-04-12",
      "last_synced_at": "2026-10-05T03:51:23.298Z",
      "location_count": 1,
      "location_summary": "Atlanta, Georgia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04559412"
    }
  ]
}